These findings, set the basis for a phase-II clinical trial with single-agent defactinib (VS-6063), an orally available ATP-competitive FAK inhibitor, in 55 heavily pretreated KRAS mutant NSCLC patients (clinical trial identifier: NCT01951690) (Gerber et al, 2020). Here, KRAS is linked to non-small cell lung carcinoma.